Skip Nav Destination
Issues
1 September 2020
-
Cover Image
Cover Image
In this issue, Wen and colleagues demonstrate that inhibition of the prolactin receptor by G129R initiates FOXO3a-mediated cell death in ovarian cancer. The confocal microscopy image on this month's cover demonstrates treatment with G129 results in nuclear accumulation of FOXO3a (in red) in a uterine cancer cell line. They further demonstrate FOX3a and EIF-4EBP1 play a critical role in the cytotoxic response to G129R. Read the full article on page 1943. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Reviews
Small Molecule Therapeutics
Author Choice
Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas
Mara Gilardi; Zhiyong Wang; Marco Proietto; Anastasia Chillà; Juan Luis Calleja-Valera; Yusuke Goto; Marco Vanoni; Matthew R. Janes; Zbigniew Mikulski; Antonio Gualberto; Alfredo A. Molinolo; Napoleone Ferrara; J. Silvio Gutkind; Francis Burrows
Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma
Sakibul Huq; Joshua Casaos; Riccardo Serra; Michael Peters; Yuanxuan Xia; Andy S. Ding; Jeff Ehresman; Jayanidhi N. Kedda; Manuel Morales; Noah L. Gorelick; Tianna Zhao; Wataru Ishida; Alexander Perdomo-Pantoja; Arba Cecia; Chenchen Ji; Ian Suk; David Sidransky; Mariana Brait; Henry Brem; Nicolas Skuli; Betty Tyler
PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis
James T. Lim; Neha Singh; Libia A. Leuvano; Valerie S. Calvert; Emanuel F. Petricoin; David T. Teachey; Richard B. Lock; Megha Padi; Andrew S. Kraft; Sathish K.R. Padi
Large Molecule Therapeutics
ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
Lillian Skidmore; Sukumar Sakamuri; Nick A. Knudsen; Amha Gebre Hewet; Snezana Milutinovic; Wisam Barkho; Sandra Lyn Biroc; Jessica Kirtley; Robin Marsden; Kristine Storey; Ianina Lopez; Wayne Yu; Shiao-Yan Fang; Sulan Yao; Yi Gu; Feng Tian
Antiproliferative Effects of Monoclonal Antibodies against (Pro)Renin Receptor in Pancreatic Ductal Adenocarcinoma
Asadur Rahman; Makoto Matsuyama; Akio Ebihara; Yuki Shibayama; Arif Ul Hasan; Hironori Nakagami; Fumiaki Suzuki; Jiao Sun; Tomoe Kobayashi; Hiroki Hayashi; Daisuke Nakano; Hideki Kobara; Tsutomu Masaki; Akira Nishiyama
Author Choice
A Novel HER2-targeted Antibody–drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels
Robyn M. Barfield; Yun Cheol Kim; Stepan Chuprakov; Fangjiu Zhang; Maxine Bauzon; Ayodele O. Ogunkoya; Dominick Yeo; Colin Hickle; Mark D. Pegram; David Rabuka; Penelope M. Drake
Author Choice
Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia
Bettina Brauchle; Rebecca L. Goldstein; Christine M. Karbowski; Anja Henn; Chi-Ming Li; Veit L. Bücklein; Christina Krupka; Michael C. Boyle; Priya Koppikar; Sascha Haubner; Joachim Wahl; Christoph Dahlhoff; Tobias Raum; Matthew J. Rardin; Christine Sastri; Dan A. Rock; Michael von Bergwelt-Baildon; Brendon Frank; Klaus H. Metzeler; Ryan Case; Matthias Friedrich; Mercedesz Balazs; Karsten Spiekermann; Angela Coxon; Marion Subklewe; Tara Arvedson
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types
James T. Topham; Emma Titmuss; Erin D. Pleasance; Laura M. Williamson; Joanna M. Karasinska; Luka Culibrk; Michael K.C. Lee; Shehara Mendis; Robert E. Denroche; Gun-Ho Jang; Steve E. Kalloger; Hui-Li Wong; Richard A. Moore; Andrew J. Mungall; Grainne M. O'Kane; Jennifer J. Knox; Steven Gallinger; Jonathan M. Loree; Dixie L. Mager; Janessa Laskin; Marco A. Marra; Steven J.M. Jones; David F. Schaeffer; Daniel J. Renouf
Cancer Biology and Translational Studies
A Novel Approach to Safer Glucocorticoid Receptor–Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition
Ekaterina A. Lesovaya; Alena V. Savinkova; Olga V. Morozova; Evgeniya S. Lylova; Ekaterina M. Zhidkova; Evgeny P. Kulikov; Kirill I. Kirsanov; Anna Klopot; Gleb Baida; Marianna G. Yakubovskaya; Leo I. Gordon; Ben Readhead; Joel T. Dudley; Irina Budunova
Statins Reduce Intratumor Cholesterol Affecting Adrenocortical Cancer Growth
Francesca Trotta; Paola Avena; Adele Chimento; Vittoria Rago; Arianna De Luca; Sara Sculco; Marta C. Nocito; Rocco Malivindi; Francesco Fallo; Raffaele Pezzani; Catia Pilon; Francesco M. Lasorsa; Simona N. Barile; Luigi Palmieri; Antonio M. Lerario; Vincenzo Pezzi; Ivan Casaburi; Rosa Sirianni
Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Taichi Mizushima; Guiyang Jiang; Takashi Kawahara; Peng Li; Bin Han; Satoshi Inoue; Hiroki Ide; Ikuma Kato; Mehrsa Jalalizadeh; Etsuko Miyagi; Mitsunori Fukuda; Leonardo O. Reis; Hiroshi Miyamoto
Correction
Correction: In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance
Abu Syed Md Anisuzzaman; Abedul Haque; Dongsheng Wang; Mohammad Aminur Rahman; Chao Zhang; Zhengjia Chen; Zhuo Georgia Chen; Dong M. Shin; A.R.M. Ruhul Amin
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.